Three Breast Cancer Drugs: FDA Warns of Rare but Serious Lung Inflammation

The US Food and Drug Administration (FDA) is warning that breast cancer drugs Ibrance (palbociclib), Kisqali (ribociclib), and Verzenio (abemaciclib) may cause rare but severe inflammation of the lungs that could lead to death.